{
  "Johnson & Johnson": {
    "2023": {
      "FORM": "8-K",
      "CATEGORIES": {
        "Section 5 - Corporate Governance and Management": {
          "ITEMS": {
            "Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers": {
              "content": "On November 30, 2023, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Eugene A. Woods, MBA, MHA, was elected to the Board of Directors.",
              "subsections": {
                "compensation": "As a non-employee director of the Company, Mr. Woods will receive compensation as described in the “Director Compensation” section of the Company’s 2023 Proxy Statement.",
                "related_transactions": "Mr. Woods is the Chief Executive Officer of Advocate Health. Advocate Health purchases the Company’s medical technologies and pharmaceuticals in the ordinary course of business. During fiscal year 2022, Advocate Health paid the Company approximately $175 million for products used in its hospitals and the Company paid Advocate Health less than $1 million in connection with clinical trials.",
                "exhibit_reference": "The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1."
              }
            }
          }
        },
        "Section 9 - Financial Statements and Exhibits": {
          "ITEMS": {
            "Item 9.01 - Financial Statements and Exhibits": {
              "content": "(d) Exhibits.",
              "subsections": {
                "Exhibit 99.1": "Press Release dated November 30, 2023",
                "Exhibit 104": "The cover page from this Current Report on Form 8-K, formatted in Inline XBRL."
              }
            }
          }
        }
      }
    }
  }
}